July 10th 2024
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
San Diego Lung Symposia
September 7, 2024 - September 8, 2024
Register Now!
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
FDA Approves Additional Dosing Option of Durvalumab for Stage III NSCLC, Advanced Bladder Cancer
November 20th 2020The FDA approved a 1500 mg fixed dose of durvalumab (Imfinzi) administered every 4 weeks for the treatment of unresectable stage III non-small cell lung cancer after chemoradiation therapy and previously treated advanced bladder cancer.
Phase 3 RATIONALE 303 Meets Primary End Point of OS in NSCLC
November 18th 2020The clinical trial is designed to evaluate the efficacy and safety of tislelizumab compared to docetaxel in the second- or third-line setting in patients with locally advanced or metastatic non-small cell lung cancer who have progressed on a prior platinum-based chemotherapy.
Patients with Early-Stage NSCLC See Higher TMB Versus Those with Advanced Stage NSCLC
November 15th 2020Researchers suggested that the tumors of patients with stage I and II early-stage non-small cell lung cancer demonstrate the highest tumor mutational burden and most often display the mutational signature associated with tobacco smoking.
Proton Radiotherapy in Patients with LA-NSCLC May Aid in Reducing Risk of Heart Disease
November 14th 2020This study found that found that mini-strokes and heart attacks were significantly less common among patients with locally advanced non-small cell lung cancer who underwent proton therapy versus conventional photon-based radiation therapy.
Study Strengthens Case for SBRT Use in Oligometastatic Neoplasia to the Lung
November 3rd 2020This study indicated that patients with up to 3 lung metastases from primary tumors in other sites who were treated with stereotactic body radiation therapy fared comparably well whether their radiation was delivered in 1 or 4 treatment sessions.
FDA Grants Priority Review to Cemiplimab-rwlc as First-Line Treatment for Advanced NSCLC
October 29th 2020The FDA granted priority review to the supplemental biologics license application for cemiplimab-rwlc (Libtayo) as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer with 50% or more PD-L1 expression.
FDA Grants Priority Review to Osimertinib for Adjuvant Treatment of Early-Stage EGFRm NSCLC
October 20th 2020The FDA accepted and granted priority review to the supplemental new drug application for osimertinib (Tagrisso) for the adjuvant treatment of patients with early-stage EGFR-mutated non-small cell lung cancer after complete tumor resection with curative intent.
Two Studies Examining Pembrolizumab Combinations Induce Positive Outcomes in Advanced NSCLC
October 19th 2020Merck announced positive data regarding 2 studies, one examining pembrolizumab in combination with chemotherapy and another in combination with quavonlimab in combination to treat advanced non-small cell lung cancer.
Phase 3 CheckMate-816 Trial Meets Primary End Point in Resectable NSCLC
October 7th 2020Significantly more patients treated with nivolumab (Opdivo) plus chemotherapy before surgery demonstrated no evidence of cancer cells in their resected tissue in the trial compared to those treated with chemotherapy alone.
Study Supports Pembrolizumab Plus Chemo as Standard of Care for PD-L1-Negative Advanced NSCLC
October 4th 2020A pooled analysis of 3 randomized controlled trials found that pembrolizumab plus chemotherapy demonstrated response and survival improvements with a manageable safety in comparison with chemotherapy alone in PD-L1‒negative advanced non-small cell lung cancer.
Atezolizumab Appears Effective for Patients with NSCLC with High PD-L1 Expression
October 1st 2020The findings from this global, open-label, randomized trial supported the FDA approval of atezolizumab for patients with non-small cell lung cancer with high PD-L1 expression, regardless of histologic type, in May.
PORT Not Recommended as Standard of Care for Completely Resected Stage IIIAN2 NSCLC
September 26th 2020Post-operative radiotherapy was associated with a nonstatistically significant increase in disease-free survival in patients with completely resected stage IIIAN2 non-small cell lung cancer and therefore cannot be recommended as a standard of care.
Phase 3 EMPOWER-Lung 1 Shows Promise for Cemiplimab-rwlc in Advanced PD-L1+ NSCLC
September 23rd 2020Cemiplimab-rwlc (Libtayo) monotherapy led to a significant improvement in overall survival and progression-free survival in patients with advanced non-small cell lung cancer with PD-L1 expression on at least 50% of their tumor cells.
Capmatinib Shows Antitumor Activity in Advanced NSCLC with a MET exon 14 Skipping Mutation
September 10th 2020Capmatinib (Tabrecta) demonstrated substantial antitumor activity in patients with advanced non-small cell lung cancer with a MET exon 14 skipping mutation, especially in those not treated previously.
FDA Approves Pralsetinib for Treatment of Adults with Metastatic RET Fusion-Positive NSCLC
September 8th 2020The approval was based on results from the phase 1/2 ARROW clinical trial, which demonstrated efficacy for pralsetinib in patients with RET fusion-positive NSCLC with or without prior therapy, and regardless of RET fusion partner or central nervous system involvement.
FDA Grants Priority Review to Tepotinib for the Treatment of NSCLC with METex14 Skipping Mutations
August 26th 2020The new drug application was based on results from the pivotal ongoing, single-arm, phase 2 VISION study evaluating tepotinib monotherapy in patients with advanced NSCLC with METex14 skipping alterations.
FDA Approves Generic Form of Pemetrexed for Non-Squamous NSCLC
August 25th 2020The FDA approved a generic form of pemetrexed for injection as a single-agent in patients with locally advanced or metastatic non-squamous non-small cell lung cancer that has not progressed after 4 cycles of first-line platinum-based chemotherapy.